Alemtuzumab/glatiramer-acetate/interferon-beta-1a: Lack of efficacy and grave's disease: case report.

Her treatment plan was 18 months of carbimazole with no intention for further treatment. Additionally, she developed grave's disease during treatment with alemtuzumab for MS [ I dosages and routes not stated i ]. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event SK, a 37-year-old woman exhibited lack of efficacy during treatment with interferon beta 1a and glatiramer acetate for multiple sclerosis (MS). [Extracted from the article]